Adial Pharmaceuticals Inc ADIL has been awarded a new U.S. patent expanding the coverage of the combination of the company’s proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and drug dependencies, such as opioid use disorder (OUD), with the company’s lead investigational new drug product AD04.
The Patent Notice of Allowance from the United States Patent and Trademark Office expands patents covering Adial’s molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence.
“Following a post hoc analysis of our ONWARD Phase 3 results, we identified patients with specific genotypes that responded extremely well to AD04. Given the positive results, we believe the combination of our genetic diagnostic and AD04 can provide a tailored treatment solution for those who suffer from AUD and OUD,” commented Cary Claiborne, CEO of Adial Pharmaceuticals.
“Among patients with the target genotypes, we believe the addressable market for AD04 is approximately $40 billion in the U.S. alone,” Claiborne added.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapies for the treatment and prevention of addiction and related disorders.
In October 2023, the company received a key patent combining the use of the company’s proprietary genetic diagnostic to detect select genotypes for genetically targeted treatment of AUD and opioid use disorder OUD with AD04.
Price Action: ADIL shares closed at $1.15 on Monday.